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Introduction 70
Due to their unique physicochemical properties, the potential utility of nanomaterials has been 71 increasingly recognised over recent years. A nanomaterial can be defined as a material which has at 72 least one dimension between 1 and 100 nm in diameter (ISO, 2008) . However, there are currently 73 multiple working definitions of a nanomaterial, which means that materials not specifically designed 74 as nanomaterials can in some instances also be classified as "nano", if for example they contain a 75 fraction in the nano-sized range of >50% of the particle count, as per the EU Recommendation (EC, 76 2011). There exists a vast array of different nanomaterials and forms that have been placed on the 77 market for numerous applications across a wide range of sectors such as cosmetics, medicine, 78 agriculture, food, textiles, electronics, packaging, and industrial chemicals (e.g. pigments (such as in 79 paints) and construction chemicals; (Nowack, 2015) ). Although the many advantages to their use are 80 clear, concerns over their safety remain. In particular it will be useful to consider the following when 81 identifying the potential risks associated with nanomaterials (Stone et al., 2016b) : 82
What are the potential consequences of nanomaterial exposure for human health and the 83
environment? 84
To what degree are humans actually exposed to nanomaterials (i.e., the likelihood that they 85 pose a risk where there is a known hazardous potential)? Consumer Safety (SCCS) has released Guidance on risk assessment of nanomaterials in cosmetics. 100
The US FDA has also recently published Guidance for Industry Use of Nanomaterials in Food for 101
Animals (FDA, 2015) . Authorisations specifically referring to (nano)materials within size boundaries 102
and/or specific forms may imply that each form of a nanomaterial used in regulated products will 103 have to be tested for safety in its own right under the appropriate regulatory framework, even 104 though some of these materials have been in production and use for many years. This approach 105 could lead to extensive testing of different nanomaterial forms, resulting from for example from 106 modifications to their size, geometry, and/or surface coatings. A desire to understand the behaviour 107 of nanomaterials throughout their life cycle/value chain could also potentially contribute towards 108 an increase in the amount of testing to understand the potential hazards to the consumer and the 109 environment at different stages of the lifecycle. Generally, the toxicity testing of nanomaterials and 110 bulk forms for regulatory purposes has been carried out primarily using a prescriptive list of animal 111 studies which have been traditionally used in the risk assessment of chemicals (e.g. studies 112
there is still a limited understanding of nanomaterial absorption, distribution, stability and 145 persistence in the (human) body (Landsiedel et al., 2012) , largely due to technological challenges 146 associated with detection of small quantities of (unlabelled) nanomaterials. Whole organisms 147 continue to be the most scientifically relevant test system as they are capable of capturing effects of 148 nanomaterials after they have been absorbed and distributed (and possibly bio-processed) in the 149 body. Furthermore, standard testing requirements in many regulations demand data from animal 150 experiments, and risk assessors are most experienced, and have most confidence, in interpreting 151 data from animal models. There is also insufficient knowledge of how results generated using non-152 animal methods compare with data from traditional in vivo tests, due to a lack of published studies 153 focused on directly comparing effects seen using alternative models (e.g. in vitro, in chemico, 154 invertebrate models) against those observed in vivo (e.g. The majority of in vivo assessments undertaken so far have been intended to assess the effects of 157 inhalation exposure to nanomaterials, as currently the primary populations at risk of exposure to 158 nanomaterials are those working in industry, and thus occupational exposure via inhalation 159 represents a high-priority group (Shatkin and Kim, 2015) . Therefore to reflect this exposure route of 160 concern, more pulmonary-orientated research than oral-based studies tends to be performed for 161 nanomaterials (Stone et al., 2016a , Aschberger et al., 2016 . Inhalation studies require specialised 162 equipment and are more difficult and expensive to carry out than oral administration studies which 163 are commonly used for other chemicals and products. Hazard assessment of nanomaterials has 164 therefore largely utilised in vivo studies carried out using high dose intratracheal instillation, with 165 Exposure assessments, which aid in the risk assessment process, are carried out with a focus on the 185 release of nanomaterials over the life cycle of the products and actual aerosol concentrations in the 186 air, with less focus on the determination of the internal body/circulating concentrations that result 187 from such exposure (Pelclova et al., 2017) . Furthermore, the patterns of exposure are likely to 188 change over coming years as the industry grows. Although inhalation exposure to nanomaterials 189 currently remains the primary portal of entry largely as a result of occupational exposure, effects on 190 consumers following exposure via oral and dermal routes are becoming more relevant due to the 191 wide array of potential applications possible for nanomaterials (e.g. in cosmetics, food or consumer 192 products), and the increase in nanomaterials on the market. Few data are available as yet on uptake 193 and effects through oral and dermal routes (Stone et al., 2016a) , as particulate materials including 194 nanomaterials are typically not often absorbed through intact skin (e.g. see SCCS, 2012 ). This is aM A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT major challenge in terms of increasing interest in the use of nanomaterials for the transdermal 196 delivery of therapeutics (e.g. reviewed in (Peptu et al., 2015) , and the use of specifically-designed 197 nanomaterials for this purpose is a further concern regarding the testing necessary to determine 198 dermal toxicity of nanomaterials. As many nanomaterials intended for dermal application are most 199 likely to be found within cosmetic products, and cosmetics are no longer allowed to be tested on 200 animals in many regions, viable alternatives to models of in vivo dermal exposure will be critical in 201 coming years. In fact, the OECD has issued guidance on an integrated approach to further sub-chronic and chronic toxicity tests need to be carried out, and in this way would decrease 247 the number of longer term studies. Indeed, as more data from this type of study becomes available 248 it could be used as a screening and grouping tool and hence reduce the need for 90 day in vivo 249 studies altogether. It is worth noting that the progression of effects and chronic outcome may not be 250 detected in such a study e.g. those which result from biopersistence. Therefore it is crucial that 251 considerations around the fitness for purpose of short-term studies are made on a case by case basis 252 (as has been previously shown in (Ferin et al., 1992) and (Oberdörster et al., 1990) ). There is also 253 potential to combine several endpoints within each animal study, and determine toxicity at both the 254 exposure site (e.g. lungs) and secondary target site (e. vivo studies that share tissues between laboratories in order to enable assessment of toxicity at 264 several target sites in one study (e.g. (Kermanizadeh et al., 2016) . 265
Increased incorporation of real-life exposure considerations when designing studies will aid in the 266 application of tiered approaches which can be used to prioritise or waive testing. This could mean 267 that nanomaterials are only tested in long-term animal studies if evidence (from in vitro testing) has 268 been gathered first which shows that there is a genuine potential risk. In this way assessments 269
would not only explore hazard potential but would also consider whether a) the nanomaterial is applications of nanoscience and nanotechnologies in the food and feed chain. There would be great 278 benefit in utilising evidence from clinical data on nanomaterial effects more widely, particularly to 279 aid understanding around likely human exposure levels, and also when evaluating the predictive 280 nature of both animal and non-animal approaches (see Table 1 ), although it is unclear how much of 281 this information exists or is likely to be generated in this timeframe. Additional information could 282 come from biomonitoring data from occupational settings, as well as initiatives that provide 283 information on the exposure levels to nanomaterials that are possible following contact with, for 284 example, different cosmetics and food products. 285
The addition of toxicokinetic analyses to short term in vivo studies could help with dose setting for 286 subsequent chronic in vivo studies, as is the case for chemicals (Creton et al., 2012). Such analyses 287 could be used to determine the relationship between internal exposure and systemic effects. This 288 information is particularly important considering that internal exposure can be influenced by pre-289 absorption behaviour of the nanomaterial (e.g. agglomeration/aggregation (Pauluhn, 2010)), or the 290 dose selected, as administration of excessively high doses may lead to higher or lower 291 (agglomeration, and thus) exposures (Oberdorster et al., 2015) . These effects highlight the 292 importance of ensuring that the doses selected for testing are relevant to levels likely to be 293 encountered by humans and the environment, and to enable cross-species extrapolation. To date, 294 assessment of nanomaterial biodistribution has relied on the use of labelled (e.g. fluorescent,
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14 biological systems which are not related to the nanomaterial itself (Johnston et al., 2013) . Elemental 297 analysis has also been used to detect and quantify nanomaterial (e.g silver) biodistribution, but this 298 approach cannot discriminate between particles or ions. Thus new approaches are required to 299 enable the biodistribution of the diverse array of unlabelled nanomaterials to be performed (for 300 example, the use of Coherent Anti-Stokes Raman Scattering (CARS) microscopy to image particle 301 uptake by cells/tissues; (Johnston et al., 2015) . 302
A further area of importance is the current efforts to evaluate, improve and validate current 303 standard in vitro test systems for nanomaterial hazard assessment. There is an appreciation that 304 approaches which already have associated OECD Test Guidelines are not always appropriate for 305 nanomaterial testing, and thus there are ongoing activities to address these issues to recommend 306 protocols developed specifically for nanomaterial evaluation (Doak et al. There is scope to leverage existing information to prioritise nanomaterials for testing. One way to 328 achieve this is through grouping, to allow the utilisation of read-across approaches and provide 329 justification for waiving of tests. There is however recognition within the field that the grouping of 330 nanomaterials is complicated and cannot be reliably carried out based on properties such as 331 chemical composition, size or surface coating alone, as the links between these and any adverse 332 The enormous diversity of nanomaterials and models (e.g. mammalian cells, rodents, humans, 374 aquatic organisms, terrestrial organisms, plants, bacteria) that must be considered is a barrier to the 375 fast development of QSARs (Kleandrova et al., 2014 ). As such, high throughput (HTP) automated 376 systems which can be used to fill data gaps are desirable to enable the generation of sufficiently 377 predictive QSAR models. Relating material properties to biological outcomes will also be useful in 378 read-across approaches, and the large body of data recently released from the OECD 379 While efforts in each of these areas are ongoing, it is important that investment continues into 427 refining and reducing the numbers of animals used in the in vivo tests that remain mandatory, and 428 from which information will be used to inform the utility of the new/adapted in vitro approaches. 429
For example, developing short-term studies for routes other than inhalation (e.g., short term studies 430 for oral administration are being developed as part of the EU-funded project SUN), and improving 431 the technical aspects of STIS, particularly as aerosol generation and characterisation is demanding. 432
Moreover, it is challenging to model actual lung burdens resulting from aerosol inhalation in vitro. 
In the long term (10 years +): Replacement with accepted non-animal methods 438
In the long-term many sectors have a desire to move away completely from using animal toxicity 439 tests towards the use of scientifically and regulatory accepted non-animal approaches which bear 440 greater relevance to humans. Like traditional in vivo tests, each non-animal method has its own 441 merits and disadvantages, and it is unlikely that one cell-based assay or computational model will 442 ever replace an existing animal test on a 1:1 basis. Thus, the most appropriate methodologies will 443 need to be applied in an integrated assessment and testing strategy (Landsiedel, 2015) , which 444 includes weight of evidence considerations. This will negate the use of a predefined test battery 445 even with suitable in vitro methods at hand. This will also mean that data packages may need to beM A N U S C R I P T
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20 designed on a case-by-case basis i.e. in a pragmatic, tiered manner which addresses the necessary 447 data gaps, rather than a conventional "tick-box" approach. 
Key objectives to achieve the vision 489
The ultimate aspiration of aligning the 3Rs principles with nanotoxicology is the efficient and reliable 490 risk assessment of nanomaterials through application of a focused, exposure-driven integrated 491 approach which utilises data from animal studies only where it genuinely adds value and 492 concentrates testing on specific scientific questions, feeding back into safe-by-design nanomaterials. 493 Table 1 outlines the expert group's perspective on the key focus areas resulting from the short, 494 medium and long-term goals and the necessary steps to enable this vision, while Provide clarity as to which potential effects can be adequately covered in safety assessment and 509 which potential effects require further research; 510
Appreciate that there will never be a single system that is suitable for all nanomaterials -511 different models/frameworks/integrated approaches (some of which are already available) 512 covering different aspects of several nanomaterials, will prove helpful; ultimately a battery of 513 approaches will cover most nanomaterials; 514
Design exposure-driven integrated approaches/decision-making frameworks first then seek the 515 methods that provide the appropriate data for this specific purpose. 516
517
Achieving the above will rely on: 518 M A N U S C R I P T
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Funding bodies, to establish strategic funding calls which have measureable impact and 521 enable the necessary progress within basic research; 522
Regulators, to provide guidance on when they can accept non-traditional approaches and 523 data (via case studies, to increase the efficiency of the case-by-case approach that is 524 recommended); and to offer compromise between relying on new approaches and 525 established methods of risk assessment, and adopting non-animal approaches. During the 526 time in which data from both in vivo and non-animal tests is being produced, their 527 concurrent consideration will help to maximise understanding of the merits and 528 disadvantages of both approaches; 529 Industry, to provide clarity about their needs and requirements, to support the steering of 530 future research efforts. 531
Finally, the output of these discussions will most likely translate into tangible impacts on the 532 reduction, refinement and replacement of animals with 1) the engagement and support from 533 
HIGHLIGHTS
An expert working group provides a current and forward looking perspective on the 3Rs in nanotoxicology Application of non-traditional, alternative methods could improve nanosafety assessment There are many short, medium and long-term opportunities to apply the 3Rs within nanotoxicology Key focus areas and steps needed to ensure genuine gains are identified.
